This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Currently meets DSM-5 criteria for diagnosis of MDD without psychotic features
Current major depressive episode of at least 4 weeks in duration
Previously participated in another clinical study of AXS-05; received any investigational drug or device treatment within 30 days of (Screening) Visit 1, or has been prescribed Auvelity.
Unable to comply with study procedures
Medically inappropriate for study participation in the opinion of the investigator